BLRX
BioLineRx Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.49
−1.70%Next report
Analyst consensus
- Next report date
- Nov 23, 2026
- EPS estimate
- -$0.39
- Revenue estimate
- $357.5K
Latest reported
- Last report date
- Aug 31, 2026
- EPS actual
- -$0.77
- EPS estimate
- -$0.15
- Revenue actual
- $294.0K
- Revenue estimate
- $500.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -67.4%
- Revenue beats (12Q)
- 3
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 31, 2026 | -$0.15 | -$0.77 | Miss -413.33% | $294.0K |
| May 27, 2026 | -$1.04 | -$0.36 | Beat 65.38% | $477.0K |
| Mar 23, 2026 | -$0.50 | -$0.34 | Beat 32.00% | $514.0K |
| Nov 24, 2025 | -$0.41 | -$0.22 | Beat 46.34% | $427.0K |
| Aug 14, 2025 | -$0.35 | -$1.00 | Miss -185.71% | $304.0K |
| May 27, 2025 | -$0.84 | $1.39 | Beat 265.48% | $255.0K |
| Mar 25, 2025 | -$4.20 | $6.00 | Beat 242.86% | $11.7M |
| Nov 25, 2024 | -$0.05 | -$2.80 | Miss -5500.00% | $4.9M |
| Aug 15, 2024 | -$0.14 | $0.40 | Beat 385.71% | $5.4M |
| May 28, 2024 | -$0.29 | -$0.01 | Beat 96.55% | $6.9M |
| Nov 20, 2023 | -$7.20 | -$12 | Miss -66.67% | — |
| Aug 30, 2023 | -$6.40 | -$12 | Miss -87.50% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 23, 2026